Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783770 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL1785691 | 0.83 | ALDH1A1 (0.50) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL13189191 | 0.82 | ALDH1A1 (0.49) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL18605357 | 0.81 | ALDH1A1 (0.48) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL4032372 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL7341365 | 0.80 | NAALAD2 (0.50) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL3719209 | 0.78 | ALDH1A1 (0.44) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL18605618 | 0.76 | ALDH1A1 (0.43) | ALDH1A1GFERHTTNPSR1FAAH | |
| SCHEMBL1303921 | 0.75 | ALDH1A1 (0.50) | ALDH1A1GFERHTTNPSR1LMNA | |
| SCHEMBL10828722 | 0.73 | ALDH1A1 (0.42) | ALDH1A1GFERHTTNPSR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | ALDH1A1 3568/4885GFER 4528/4885HTT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.